Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer

Harold Harvey, Allan Lipton, D. T. Max, H. G. Pearlman, R. Diaz-Perches, J. de la Garza

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

Leuprolide (Lupron, TAP Pharmaceuticals, North Chicago), a gonadotropin-releasing hormone analogue, was administered to 26 premenopausal women with metastatic breast cancer. Of 25 evaluable patients, 11 (44%) had a partial response with a medium duration of 39 weeks and five (20%) remained stable. Six patients showed early rapid progression of their disease. Toxicity was mild and included hot flashes, nausea, vomiting, and headache. Leuprolide induced amenorrhea in all patients who received treatment for ten weeks or longer. We conclude that this GnRH analogue provides a safe and effective means of producing medical castration in premenopausal patients with metastatic breast carcinoma.

Original languageEnglish (US)
Pages (from-to)1068-1072
Number of pages5
JournalJournal of Clinical Oncology
Volume3
Issue number8
DOIs
StatePublished - 1985

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this